Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

Science 316 (5827): 1039-1043

Copyright © 2007 by the American Association for the Advancement of Science

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman,1,2,3 Kreshnik Zejnullahu,4,5 Tetsuya Mitsudomi,6 Youngchul Song,2,3 Courtney Hyland,7 Joon Oh Park,4,5 Neal Lindeman,7 Christopher-Michael Gale,3 Xiaojun Zhao,5 James Christensen,8 Takayuki Kosaka,6 Alison J. Holmes,4,5 Andrew M. Rogers,5 Federico Cappuzzo,9 Tony Mok,10 Charles Lee,7 Bruce E. Johnson,4,5 Lewis C. Cantley,2,3 Pasi A. Jänne4,5*

Abstract: The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib. MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib. We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)–dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors. Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.

1 Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
2 Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
3 Department of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
4 Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
5 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
6 Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.
7 Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
8 Pfizer Global Research and Development, Department of Research Pharmacology, La Jolla Laboratories, La Jolla, CA 92121, USA.
9 Istituto Clinico Humanitas, Department on Hematology-Oncology, Rozzano 20089, Italy.
10 Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China.

* To whom correspondence should be addressed. E-mail: pjanne{at}partners.org


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer.
J. M. Drake, J. K. Lee, and O. N. Witte (2014)
Mol. Cell. Biol. 34, 1722-1732
   Abstract »    Full Text »    PDF »
Dynamic Reprogramming of Signaling Upon Met Inhibition Reveals a Mechanism of Drug Resistance in Gastric Cancer.
A. Z. Lai, S. Cory, H. Zhao, M. Gigoux, A. Monast, M.-C. Guiot, S. Huang, A. Tofigh, C. Thompson, M. Naujokas, et al. (2014)
Science Signaling 7, ra38
   Abstract »    Full Text »    PDF »
Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data.
W. W. Chen, B. Schoeberl, P. J. Jasper, M. Niepel, U. B. Nielsen, D. A. Lauffenburger, and P. K. Sorger (2014)
Mol Syst Biol 5, 239
   Abstract »    Full Text »    PDF »
Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities.
D. K. Singh, C.-J. Ku, C. Wichaidit, R. J. Steininger III, L. F. Wu, and S. J. Altschuler (2014)
Mol Syst Biol 6, 369
   Abstract »    Full Text »    PDF »
The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.
K. Komurov, J.-T. Tseng, M. Muller, E. G. Seviour, T. J. Moss, L. Yang, D. Nagrath, and P. T. Ram (2014)
Mol Syst Biol 8, 596
   Abstract »    Full Text »    PDF »
Bosutinib Reduces the Efficacy of Dasatinib in Triple-negative Breast Cancer Cell Lines.
M. TARPLEY, T. T. ABDISSA, G. L. JOHNSON, and J. E. SCOTT (2014)
Anticancer Res 34, 1629-1635
   Abstract »    Full Text »    PDF »
Phase II Study of Erlotinib for Acquired Resistance to Gefitinib in Patients with Advanced Non-small Cell Lung Cancer.
A. HORIIKE, N. YAMAMOTO, H. TANAKA, N. YANAGITANI, K. KUDO, F. OHYANAGI, A. ONO, T. NAITO, H. MURAKAMI, T. HORAI, et al. (2014)
Anticancer Res 34, 1975-1981
   Abstract »    Full Text »    PDF »
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.
J. Li, K. Bennett, A. Stukalov, B. Fang, G. Zhang, T. Yoshida, I. Okamoto, J.-Y. Kim, L. Song, Y. Bai, et al. (2014)
Mol Syst Biol 9, 705
   Abstract »    Full Text »    PDF »
Interactions of ion transporters and channels with cancer cell metabolism and the tumour microenvironment.
A. P. Andersen, J. M. A. Moreira, and S. F. Pedersen (2014)
Phil Trans R Soc B 369, 20130098
   Abstract »    Full Text »    PDF »
Molecular Pathways: HER3 Targeted Therapy.
K. Gala and S. Chandarlapaty (2014)
Clin. Cancer Res. 20, 1410-1416
   Abstract »    Full Text »    PDF »
Tumor heterogeneity in the clinic: is it a real problem?.
F. Janku (2014)
Therapeutic Advances in Medical Oncology 6, 43-51
   Abstract »    PDF »
Role of erbB3 receptors in cancer therapeutic resistance.
Y. Lee, J. Ma, H. Lyu, J. Huang, A. Kim, and B. Liu (2014)
Acta Biochim Biophys Sin 46, 190-198
   Abstract »    Full Text »    PDF »
Vandetanib for the Treatment of Medullary Thyroid Carcinoma.
M. R. Cooper, S. Y. Yi, W. Alghamdi, D. J. Shaheen, and M. Steinberg (2014)
Annals of Pharmacotherapy 48, 387-394
   Abstract »    Full Text »    PDF »
Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas.
A. Boin, A. Couvelard, C. Couderc, I. Brito, D. Filipescu, M. Kalamarides, P. Bedossa, L. De Koning, C. Danelsky, T. Dubois, et al. (2014)
Neuro Oncology
   Abstract »    Full Text »    PDF »
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer.
S. Misale, S. Arena, S. Lamba, G. Siravegna, A. Lallo, S. Hobor, M. Russo, M. Buscarino, L. Lazzari, A. Sartore-Bianchi, et al. (2014)
Science Translational Medicine 6, 224ra26
   Abstract »    Full Text »    PDF »
EMT Twists the Road to PI3K.
M. J. Niederst and C. H. Benes (2014)
Cancer Discovery 4, 149-151
   Abstract »    Full Text »    PDF »
Assessment of Intratumoral Heterogeneity of Oncogenic Driver Mutations in Surgically-resected Lung Adenocarcinoma: Implications of Percutaneous Biopsy-based Molecular Assay for Target-directed Therapy.
H. K. KIM, H. Y. LEE, Y.-L. CHOI, S.-J. CHOI, H. CHOI, J. LEE, J. HAN, M.-J. AHN, K. S. LEE, and J. KIM (2014)
Anticancer Res 34, 707-714
   Abstract »    Full Text »    PDF »
Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non-Small Cell Lung Cancer.
I. Kawada, R. Hasina, Q. Arif, J. Mueller, E. Smithberger, A. N. Husain, E. E. Vokes, and R. Salgia (2014)
Cancer Res. 74, 884-895
   Abstract »    Full Text »    PDF »
Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss.
E. M. Beauchamp, B. A. Woods, A. M. Dulak, L. Tan, C. Xu, N. S. Gray, A. J. Bass, K.-k. Wong, M. Meyerson, and P. S. Hammerman (2014)
Mol. Cancer Ther. 13, 475-482
   Abstract »    Full Text »    PDF »
MiR-134/487b/655 Cluster Regulates TGF-{beta}-Induced Epithelial-Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells.
K. Kitamura, M. Seike, T. Okano, K. Matsuda, A. Miyanaga, H. Mizutani, R. Noro, Y. Minegishi, K. Kubota, and A. Gemma (2014)
Mol. Cancer Ther. 13, 444-453
   Abstract »    Full Text »    PDF »
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy.
G. D. L. Phillips, C. T. Fields, G. Li, D. Dowbenko, G. Schaefer, K. Miller, F. Andre, H. A. Burris III, K. S. Albain, N. Harbeck, et al. (2014)
Clin. Cancer Res. 20, 456-468
   Abstract »    Full Text »    PDF »
The Current State of Molecularly Targeted Drugs Targeting HGF/Met.
S. Yano and T. Nakagawa (2014)
Jpn. J. Clin. Oncol. 44, 9-12
   Abstract »    Full Text »    PDF »
MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation.
J. K. Rho, Y. J. Choi, S. Y. Kim, T. W. Kim, E. K. Choi, S.-J. Yoon, B. M. Park, E. Park, J. H. Bae, C.-M. Choi, et al. (2014)
Cancer Res. 74, 253-262
   Abstract »    Full Text »    PDF »
ERK1/2 Blockade Prevents Epithelial-Mesenchymal Transition in Lung Cancer Cells and Promotes Their Sensitivity to EGFR Inhibition.
J. M. Buonato and M. J. Lazzara (2014)
Cancer Res. 74, 309-319
   Abstract »    Full Text »    PDF »
Therapeutic target database update 2014: a resource for targeted therapeutics.
C. Qin, C. Zhang, F. Zhu, F. Xu, S. Y. Chen, P. Zhang, Y. H. Li, S. Y. Yang, Y. Q. Wei, L. Tao, et al. (2014)
Nucleic Acids Res. 42, D1118-D1123
   Abstract »    Full Text »    PDF »
Increased TGF-{alpha} as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells.
T. Troiani, E. Martinelli, S. Napolitano, D. Vitagliano, L. P. Ciuffreda, S. Costantino, F. Morgillo, A. Capasso, V. Sforza, A. Nappi, et al. (2013)
Clin. Cancer Res. 19, 6751-6765
   Abstract »    Full Text »    PDF »
The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models.
N. Miyajima, S. Tsutsumi, C. Sourbier, K. Beebe, M. Mollapour, C. Rivas, S. Yoshida, J. B. Trepel, Y. Huang, M. Tatokoro, et al. (2013)
Cancer Res. 73, 7022-7033
   Abstract »    Full Text »    PDF »
Genomic Aberrations Associated with Erlotinib Resistance in Non-small Cell Lung Cancer Cells.
M. SERIZAWA, T. TAKAHASHI, N. YAMAMOTO, and Y. KOH (2013)
Anticancer Res 33, 5223-5233
   Abstract »    Full Text »    PDF »
Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC.
A. O. Walter, R. T. T. Sjin, H. J. Haringsma, K. Ohashi, J. Sun, K. Lee, A. Dubrovskiy, M. Labenski, Z. Zhu, Z. Wang, et al. (2013)
Cancer Discovery 3, 1404-1415
   Abstract »    Full Text »    PDF »
Cetuximab Response of Lung Cancer-Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization.
J. Cho, L. Chen, N. Sangji, T. Okabe, K. Yonesaka, J. M. Francis, R. J. Flavin, W. Johnson, J. Kwon, S. Yu, et al. (2013)
Cancer Res. 73, 6770-6779
   Abstract »    Full Text »    PDF »
Signaling Control by Epidermal Growth Factor Receptor and MET: Rationale for Cotargeting Strategies in Lung Cancer.
E. B. Haura and M. A. Smith (2013)
J. Clin. Oncol. 31, 4148-4150
   Full Text »    PDF »
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer.
J. F. Gainor and A. T. Shaw (2013)
J. Clin. Oncol. 31, 3987-3996
   Abstract »    Full Text »    PDF »
Homology-mediated end-capping as a primary step of sister chromatid fusion in the breakage-fusion-bridge cycles.
M. Marotta, X. Chen, T. Watanabe, P. W. Faber, S. J. Diede, S. Tapscott, R. Tubbs, A. Kondratova, R. Stephens, and H. Tanaka (2013)
Nucleic Acids Res. 41, 9732-9740
   Abstract »    Full Text »    PDF »
Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?.
S. J. C. van der Stegen, D. M. Davies, S. Wilkie, J. Foster, J. K. Sosabowski, J. Burnet, L. M. Whilding, R. M. Petrovic, S. Ghaem-Maghami, S. Mather, et al. (2013)
J. Immunol. 191, 4589-4598
   Abstract »    Full Text »    PDF »
MicroRNA Signature Helps Distinguish Early from Late Biochemical Failure in Prostate Cancer.
Z. Lichner, A. Fendler, C. Saleh, A. N. Nasser, D. Boles, S. Al-Haddad, P. Kupchak, M. Dharsee, P. S. Nuin, K. R. Evans, et al. (2013)
Clin. Chem. 59, 1595-1603
   Abstract »    Full Text »    PDF »
A Highly Potent and Specific MET Therapeutic Protein Antagonist with Both Ligand-Dependent and Ligand-Independent Activity.
S. A. Olwill, C. Joffroy, H. Gille, E. Vigna, G. Matschiner, A. Allersdorfer, B. M. Lunde, J. Jaworski, J. F. Burrows, C. Chiriaco, et al. (2013)
Mol. Cancer Ther. 12, 2459-2471
   Abstract »    Full Text »    PDF »
Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin {beta}1/Src/Akt-Driven Bypass Signaling.
R. Kanda, A. Kawahara, K. Watari, Y. Murakami, K. Sonoda, M. Maeda, H. Fujita, M. Kage, H. Uramoto, C. Costa, et al. (2013)
Cancer Res. 73, 6243-6253
   Abstract »    Full Text »    PDF »
Inhibition of Tumor Growth and Metastasis in Non-Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET.
W. Wu, C. Bi, K. M. Credille, J. R. Manro, V. L. Peek, G. P. Donoho, L. Yan, J. A. Wijsman, S. B. Yan, and R. A. Walgren (2013)
Clin. Cancer Res. 19, 5699-5710
   Abstract »    Full Text »    PDF »
Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer.
B. Izar, J. Rotow, J. Gainor, J. Clark, and B. Chabner (2013)
Pharmacol. Rev. 65, 1351-1395
   Abstract »    Full Text »    PDF »
From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development.
C. H. Lieu, A.-C. Tan, S. Leong, J. R. Diamond, and S. G. Eckhardt (2013)
J Natl Cancer Inst 105, 1441-1456
   Abstract »    Full Text »    PDF »
A systematic approach to therapeutic target selection in oesophago-gastric cancer.
A. L. Paterson, N. B. Shannon, P. Lao-Sirieix, C.-A. J. Ong, C. J. Peters, M. O'Donovan, and R. C. Fitzgerald (2013)
Gut 62, 1415-1424
   Abstract »    Full Text »    PDF »
Fibroblast growth factor receptors, developmental corruption and malignant disease.
F. C. Kelleher, H. O'Sullivan, E. Smyth, R. McDermott, and A. Viterbo (2013)
Carcinogenesis 34, 2198-2205
   Abstract »    Full Text »    PDF »
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin.
A. P. Garner, C. U. Bialucha, E. R. Sprague, J. T. Garrett, Q. Sheng, S. Li, O. Sineshchekova, P. Saxena, C. R. Sutton, D. Chen, et al. (2013)
Cancer Res. 73, 6024-6035
   Abstract »    Full Text »    PDF »
Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.
S. Dacic (2013)
J. Clin. Pathol. 66, 870-874
   Abstract »    Full Text »    PDF »
Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer.
M. J. Niederst and J. A. Engelman (2013)
Science Signaling 6, re6
   Abstract »    Full Text »    PDF »
Cell-Autonomous and Non-Cell-Autonomous Mechanisms of HGF/MET-Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective.
S. Corso and S. Giordano (2013)
Cancer Discovery 3, 978-992
   Abstract »    Full Text »    PDF »
Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance.
P. Jia, H. Jin, C. B. Meador, J. Xia, K. Ohashi, L. Liu, V. Pirazzoli, K. B. Dahlman, K. Politi, F. Michor, et al. (2013)
Genome Res. 23, 1434-1445
   Abstract »    Full Text »    PDF »
Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
M. M. Sak, M. Szymanska, V. Bertelsen, M. Hasmann, I. H. Madshus, and E. Stang (2013)
Carcinogenesis 34, 2031-2038
   Abstract »    Full Text »    PDF »
Synergistic Chemoimmunotherapy of Epithelial Ovarian Cancer Using ErbB-Retargeted T Cells Combined with Carboplatin.
A. C. Parente-Pereira, L. M. Whilding, N. Brewig, S. J. C. van der Stegen, D. M. Davies, S. Wilkie, M. C. I. van Schalkwyk, S. Ghaem-Maghami, and J. Maher (2013)
J. Immunol. 191, 2437-2445
   Abstract »    Full Text »    PDF »
MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate Resistance.
A. K. Paulson, E. S. Linklater, B. D. Berghuis, C. A. App, L. D. Oostendorp, J. E. Paulson, J. E. Pettinga, M. K. Melnik, G. F. Vande Woude, and C. R. Graveel (2013)
Mol. Cancer Res. 11, 1112-1121
   Abstract »    Full Text »    PDF »
EGF Receptor Activates MET through MAPK to Enhance Non-Small Cell Lung Carcinoma Invasion and Brain Metastasis.
J. L. Breindel, J. W. Haskins, E. P. Cowell, M. Zhao, D. X. Nguyen, and D. F. Stern (2013)
Cancer Res. 73, 5053-5065
   Abstract »    Full Text »    PDF »
RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation.
C. Mirschberger, C. B. Schiller, M. Schraml, N. Dimoudis, T. Friess, C. A. Gerdes, U. Reiff, V. Lifke, G. Hoelzlwimmer, I. Kolm, et al. (2013)
Cancer Res. 73, 5183-5194
   Abstract »    Full Text »    PDF »
Dual Roles of the Transcription Factor Grainyhead-like 2 (GRHL2) in Breast Cancer.
S. Werner, S. Frey, S. Riethdorf, C. Schulze, M. Alawi, L. Kling, V. Vafaizadeh, G. Sauter, L. Terracciano, U. Schumacher, et al. (2013)
J. Biol. Chem. 288, 22993-23008
   Abstract »    Full Text »    PDF »
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
J. K. Lee, J.- Y. Shin, S. Kim, S. Lee, C. Park, J.- Y. Kim, Y. Koh, B. Keam, H. S. Min, T. M. Kim, et al. (2013)
Ann. Onc. 24, 2080-2087
   Abstract »    Full Text »    PDF »
Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling.
B. J. Quinn, M. Dallos, H. Kitagawa, A. B. Kunnumakkara, R. M. Memmott, M. C. Hollander, J. J. Gills, and P. A. Dennis (2013)
Cancer Prevention Research 6, 801-810
   Abstract »    Full Text »    PDF »
Strengthening Context-Dependent Anticancer Effects on Non-Small Cell Lung Carcinoma by Inhibition of Both MET and EGFR.
Y.-W. Zhang, B. Staal, C. Essenburg, S. Lewis, D. Kaufman, and G. F. Vande Woude (2013)
Mol. Cancer Ther. 12, 1429-1441
   Abstract »    Full Text »    PDF »
USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer.
S. Byun, S.-Y. Lee, J. Lee, C.-H. Jeong, L. Farrand, S. Lim, K. Reddy, J. Y. Kim, M.-H. Lee, H. J. Lee, et al. (2013)
Clin. Cancer Res. 19, 3894-3904
   Abstract »    Full Text »    PDF »
Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC.
H. Terai, K. Soejima, H. Yasuda, S. Nakayama, J. Hamamoto, D. Arai, K. Ishioka, K. Ohgino, S. Ikemura, T. Sato, et al. (2013)
Mol. Cancer Res. 11, 759-767
   Abstract »    Full Text »    PDF »
MET: A Critical Player in Tumorigenesis and Therapeutic Target.
C. R. Graveel, D. Tolbert, and G. F. Vande Woude (2013)
Cold Spring Harb Perspect Biol 5, a009209
   Abstract »    Full Text »    PDF »
Evolutionary dynamics of cancer in response to targeted combination therapy.
I. Bozic, J. G. Reiter, B. Allen, T. Antal, K. Chatterjee, P. Shah, Y. S. Moon, A. Yaqubie, N. Kelly, D. T. Le, et al. (2013)
eLife Sci 2, e00747
   Abstract »    Full Text »    PDF »
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer.
A. Bardelli, S. Corso, A. Bertotti, S. Hobor, E. Valtorta, G. Siravegna, A. Sartore-Bianchi, E. Scala, A. Cassingena, D. Zecchin, et al. (2013)
Cancer Discovery 3, 658-673
   Abstract »    Full Text »    PDF »
Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion.
J. Wang, N. W. Pursell, M. E. S. Samson, R. Atoyan, A. W. Ma, A. Selmi, W. Xu, X. Cai, M. Voi, P. Savagner, et al. (2013)
Mol. Cancer Ther. 12, 925-936
   Abstract »    Full Text »    PDF »
A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities.
Y. Awazu, K. Nakamura, A. Mizutani, Y. Kakoi, H. Iwata, S. Yamasaki, N. Miyamoto, S. Imamura, H. Miki, and A. Hori (2013)
Mol. Cancer Ther. 12, 913-924
   Abstract »    Full Text »    PDF »
Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors.
P. LoRusso, P. A. Janne, M. Oliveira, N. Rizvi, L. Malburg, V. Keedy, L. Yee, C. Copigneaux, T. Hettmann, C.-Y. Wu, et al. (2013)
Clin. Cancer Res. 19, 3078-3087
   Abstract »    Full Text »    PDF »
Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2.
M. Acunzo, G. Romano, D. Palmieri, A. Lagana, M. Garofalo, V. Balatti, A. Drusco, M. Chiariello, P. Nana-Sinkam, and C. M. Croce (2013)
PNAS 110, 8573-8578
   Abstract »    Full Text »    PDF »
Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges.
R. Dienstmann, J. Rodon, J. Barretina, and J. Tabernero (2013)
J. Clin. Oncol. 31, 1874-1884
   Abstract »    Full Text »    PDF »
Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment.
R. Buettner, J. Wolf, and R. K. Thomas (2013)
J. Clin. Oncol. 31, 1858-1865
   Abstract »    Full Text »    PDF »
Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-like Properties in Cancer Cells.
K. Shien, S. Toyooka, H. Yamamoto, J. Soh, M. Jida, K. L. Thu, S. Hashida, Y. Maki, E. Ichihara, H. Asano, et al. (2013)
Cancer Res. 73, 3051-3061
   Abstract »    Full Text »    PDF »
Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition.
R. Katayama, A. Aoyama, T. Yamori, J. Qi, T. Oh-hara, Y. Song, J. A. Engelman, and N. Fujita (2013)
Cancer Res. 73, 3087-3096
   Abstract »    Full Text »    PDF »
A Network of Substrates of the E3 Ubiquitin Ligases MDM2 and HUWE1 Control Apoptosis Independently of p53.
M. Kurokawa, J. Kim, J. Geradts, K. Matsuura, L. Liu, X. Ran, W. Xia, T. J. Ribar, R. Henao, M. W. Dewhirst, et al. (2013)
Science Signaling 6, ra32
   Abstract »    Full Text »    PDF »
De-Repression of PDGFR{beta} Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients.
D. Akhavan, A. L. Pourzia, A. A. Nourian, K. J. Williams, D. Nathanson, I. Babic, G. R. Villa, K. Tanaka, A. Nael, H. Yang, et al. (2013)
Cancer Discovery 3, 534-547
   Abstract »    Full Text »    PDF »
Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model.
T. Ninomiya, N. Takigawa, E. Ichihara, N. Ochi, T. Murakami, Y. Honda, T. Kubo, D. Minami, K. Kudo, M. Tanimoto, et al. (2013)
Mol. Cancer Ther. 12, 589-597
   Abstract »    Full Text »    PDF »
Crizotinib Induces PUMA-Dependent Apoptosis in Colon Cancer Cells.
X. Zheng, K. He, L. Zhang, and J. Yu (2013)
Mol. Cancer Ther. 12, 777-786
   Abstract »    Full Text »    PDF »
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers.
H. A. Yu, M. E. Arcila, N. Rekhtman, C. S. Sima, M. F. Zakowski, W. Pao, M. G. Kris, V. A. Miller, M. Ladanyi, and G. J. Riely (2013)
Clin. Cancer Res. 19, 2240-2247
   Abstract »    Full Text »    PDF »
Erlotinib Prolongs Survival in Pancreatic Cancer by Blocking Gemcitabine-Induced MAPK Signals.
K. Miyabayashi, H. Ijichi, D. Mohri, M. Tada, K. Yamamoto, Y. Asaoka, T. Ikenoue, K. Tateishi, Y. Nakai, H. Isayama, et al. (2013)
Cancer Res. 73, 2221-2234
   Abstract »    Full Text »    PDF »
Downregulation of HER3 by a Novel Antisense Oligonucleotide, EZN-3920, Improves the Antitumor Activity of EGFR and HER2 Tyrosine Kinase Inhibitors in Animal Models.
Y. Wu, Y. Zhang, M. Wang, Q. Li, Z. Qu, V. Shi, P. Kraft, S. Kim, Y. Gao, J. Pak, et al. (2013)
Mol. Cancer Ther. 12, 427-437
   Abstract »    Full Text »    PDF »
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy.
P. Yeh, H. Chen, J. Andrews, R. Naser, W. Pao, and L. Horn (2013)
Clin. Cancer Res. 19, 1894-1901
   Abstract »    Full Text »    PDF »
Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition.
Y. Zhang, K. E. Farenholtz, Y. Yang, F. Guessous, C. G. diPierro, V. S. Calvert, J. Deng, D. Schiff, W. Xin, J. K. Lee, et al. (2013)
Clin. Cancer Res. 19, 1433-1444
   Abstract »    Full Text »    PDF »
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Disease.
K. Ohashi, Y. E. Maruvka, F. Michor, and W. Pao (2013)
J. Clin. Oncol. 31, 1070-1080
   Abstract »    Full Text »    PDF »
Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non-Small-Cell Lung Cancer.
S. A. Laurie and G. D. Goss (2013)
J. Clin. Oncol. 31, 1061-1069
   Abstract »    Full Text »    PDF »
MET As a Possible Target for Non-Small-Cell Lung Cancer.
A. A. Sadiq and R. Salgia (2013)
J. Clin. Oncol. 31, 1089-1096
   Abstract »    Full Text »    PDF »
ALK in Lung Cancer: Past, Present, and Future.
A. T. Shaw and J. A. Engelman (2013)
J. Clin. Oncol. 31, 1105-1111
   Abstract »    Full Text »    PDF »
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers.
H. A. Yu and G. J. Riely (2013)
J Natl Compr Canc Netw 11, 161-169
   Abstract »    Full Text »    PDF »
Pertuzumab: new hope for patients with HER2-positive breast cancer.
M. Capelan, L. Pugliano, E. De Azambuja, I. Bozovic, K. S. Saini, C. Sotiriou, S. Loi, and M. J. Piccart-Gebhart (2013)
Ann. Onc. 24, 273-282
   Abstract »    Full Text »    PDF »
Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function.
J. T. Garrett, C. R. Sutton, M. G. Kuba, R. S. Cook, and C. L. Arteaga (2013)
Clin. Cancer Res. 19, 610-619
   Abstract »    Full Text »    PDF »
The Role of MET Receptor Tyrosine Kinase in Non-Small Cell Lung Cancer and Clinical Development of Targeted Anti-MET Agents.
K. W. Robinson and A. B. Sandler (2013)
Oncologist 18, 115-122
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882